Skip to Content
Merck
CN

47319

Fmoc-D-Tyr(tBu)-OH

≥98.0% (HPLC)

Synonym(s):

Fmoc-O-tert-butyl-D-tyrosine

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C28H29NO5
CAS Number:
118488-18-9
Molecular Weight:
459.53
NACRES:
NA.26
PubChem Substance ID:
57650924
eCl@ss:
32160406
UNSPSC Code:
12352209
MDL number:
MFCD00065684
Beilstein/REAXYS Number:
6691868

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Fmoc-D-Tyr(tBu)-OH, ≥98.0% (HPLC)

InChI

1S/C28H29NO5/c1-28(2,3)34-19-14-12-18(13-15-19)16-25(26(30)31)29-27(32)33-17-24-22-10-6-4-8-20(22)21-9-5-7-11-23(21)24/h4-15,24-25H,16-17H2,1-3H3,(H,29,32)(H,30,31)/t25-/m1/s1

SMILES string

CC(C)(C)Oc1ccc(C[C@@H](NC(=O)OCC2c3ccccc3-c4ccccc24)C(O)=O)cc1

InChI key

JAUKCFULLJFBFN-RUZDIDTESA-N

assay

≥98.0% (HPLC)

form

solid

reaction suitability

reaction type: Fmoc solid-phase peptide synthesis

application(s)

peptide synthesis

functional group

Fmoc

storage temp.

2-8°C

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCC0617
BCBV8161
BCBD4561V
BCBN2002V
1411364

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kazuma Ogawa et al.
Chemical & pharmaceutical bulletin, 66(6), 651-659 (2018-06-05)
Radiolabeled cyclic peptides containing the (Arg-Gly-Asp) RGD sequence for use in positron emission tomography (PET) imaging, single-photon emission computed tomography (SPECT) imaging, and targeted radionuclide therapy of cancer have been reported. In this study, RGD was used as a model
Fayçal Touti et al.
Nature chemical biology, 15(4), 410-418 (2019-03-20)
The use of competitive inhibitors to disrupt protein-protein interactions (PPIs) holds great promise for the treatment of disease. However, the discovery of high-affinity inhibitors can be a challenge. Here we report a platform for improving the affinity of peptide-based PPI
Andreas Pech et al.
Nucleic acids research, 45(7), 3997-4005 (2017-02-06)
Biological evolution resulted in a homochiral world in which nucleic acids consist exclusively of d-nucleotides and proteins made by ribosomal translation of l-amino acids. From the perspective of synthetic biology, however, particularly anabolic enzymes that could build the mirror-image counterparts

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service